C-terminal peptides of calcitonin gene-related peptide act as agonists at the cholecystokinin receptor.
We have previously described that [Tyr0]CGRP(28-37) acts as a receptor antagonist of rat CGRP in guinea pig pancreatic acini. We therefore examined other C-terminal peptides of CGRP for such activity. CGRP-acetyl(28-37) acetate did act as a rat CGRP antagonist. However, C-terminal CGRP peptides of 4 to 8 amino acid residues did not antagonize the actions of rat CGRP but stimulated amylase secretion. In pancreatic acini, a maximally effective concentration of rat CGRP (100 nM) caused a 2.1-fold increase in amylase secretion. When the C-terminal peptides of CGRP were tested in at 100 microM, CGRP(34-37) caused a 1.8-fold increase in amylase secretion, CGRP(33-37) a 2.8-fold increase. CGRP(32-37) a 9.2-fold increase, CGRP(31-37) a 4.1-fold increase, and CGRP(30-37) a 5.1-fold increase. Further studies with the most effective peptide, CGRP(32-37), demonstrated that it did not cause release of lactate dehydrogenase, and thus did not cause amylase release by cell damage. Unlike rat CGRP, CGRP(32-37) did not increase cellular cyclic AMP, but did stimulate outflux of 45Ca. CGRP(32-37)-stimulated amylase release was not inhibited by the substance P receptor antagonist, spantide, by the bombesin receptor antagonist, [D-Phe6]bombesin(6-13) propylamide, or by the muscarinic receptor antagonist, atropine, but was inhibited by the CCK receptor antagonist L364,718. C-terminal peptides of CGRP inhibited binding of 125I-BH-CCK-8, with the relative potencies of the peptides being the same as their relative potencies for stimulating amylase secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
Maton
P N
PN
Digestive Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Pradhan
T
T
Moore
S
S
D000595:Amino Acid Sequence; D000681:Amylases / Q000378:metabolism; D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000032:analysis; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D008969:Molecular Sequence Data; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology*; D011869:Radioligand Assay; D011949:Receptors, Cholecystokinin / Q000187:drug effects*
D010446:Peptide Fragments; D011949:Receptors, Cholecystokinin; D000242:Cyclic AMP; D007770:L-Lactate Dehydrogenase; D000681:Amylases; D015740:Calcitonin Gene-Related Peptide; D002118:Calcium